High dopamine turnover in the brains of Sandy mice

Neuroscience Letters

Volumn 421, Issue 1, 2007, Pages 47-51

  Murotani, Tomotaka ^a   Ishizuka, Tomoko ^a   Hattori, Satoko ^b   Hashimoto, Ryota ^a   Matsuzaki, Shinsuke ^a   Yamatodani, Atsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Dopamine; Dopamine turnover; Dysbindin; Homovanillic acid; Sandy mice; Schizophrenia

Indexed keywords

DOPAMINE; DYSBINDIN PROTEIN; DYSTROBREVIN; HOMOVANILLIC ACID; PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MESENCEPHALON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CARRIER PROTEINS; DOPAMINE; HOMOVANILLIC ACID; MALE; MICE; MICE, INBRED DBA; MICE, MUTANT STRAINS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 34250205954     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.05.019     Document Type: Article

References (35)

1. Brouwer N., Van Dijken H., Ruiters M.H., Van Willigen J.D., and Ter Horst G.J. Localization of dopamine D2 receptor mRNA with non-radioactive in situ hybridization histochemistry. Neurosci. Lett. 142 (1992) 223-227
2. Chiba S., Hashimoto R., Hattori S., Yohda M., Lipska B., Weinberger D.R., and Kunugi H. Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. J. Neural Transm. 113 (2006) 1337-1346
3. Datta P.C., and King M.G. Alpha-melanocyte-stimulating hormone and behavior. Neurosci. Biobehav. Rev. 6 (1982) 297-310
4. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 48 (1991) 1474-1486
5. Deutch A.Y., Tam S.Y., Freeman A.S., Bowers Jr. M.B., and Roth R.H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur. J. Pharmacol. 134 (1987) 257-264
6. Glowinski J., and Iversen L.L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
7. Hashimoto R., Hattori S., Chiba S., Yagasaki Y., Okada T., Kumamaru E., Mori T., Nemoto K., Tanii H., Hori H., Noguchi H., Numakawa T., Ohnishi T., and Kunugi H. Susceptibility genes for schizophrenia. Psychiatry Clin. Neurosci. 60 Suppl. 1 (2006) S4-S10
8. Hasue R.H., and Shammah-Lagnado S.J. Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. J. Comp. Neurol. 99 (2002) 15-33
9. Holzbauer M., and Racke K. The dopaminergic innervation of the intermediate lobe and of the neural lobe of the pituitary gland. Med. Biol. 63 (1985) 97-116
10. Joyal C.C., Laakso M.P., Tiihonen J., Syvalahti E., Vilkman H., Laakso A., Alakare B., Rakkolainen V., Salokangas R.K., and Hietala J. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients. Biol. Psychiatry 54 (2003) 1302-1304
11. Kumamoto N., Matsuzaki S., Inoue K., Hattori T., Shimizu S., Hashimoto R., Yamatodani A., Katayama T., and Tohyama M. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochem. Biophys Res. Commun. 345 (2006) 904-909
12. Li W., Zhang Q., Oiso N., Novak E.K., Gautam R., O'Brien E.P., Tinsley C.L., Blake D.J., Spritz R.A., Copeland N.G., Jenkins N.A., Amato D., Roe B.A., Starcevic M., Dell'Angelica E.C., Elliott R.W., Mishra V., Kingsmore S.F., Paylor R.E., and Swank R.T. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat. Genet. 33 (2003) 84-89
13. Lisman J.E., and Grace A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46 (2005) 703-713
14. Matsumoto M., Weickert C.S., Beltaifa S., Kolachana B., Chen J., Hyde T.M., Herman M.M., Weinberger D.R., and Kleinman J.E. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 116 (2003) 1521-1530
15. Meador-Woodruff J.H., Mansour A., Healy D.J., Kuehn R., Zhou Q.Y., Bunzow J.R., Akil H., Civelli O., and Watson Jr. S.J. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology 30 (1991) 231-242
16. Mengod G., Villaro M.T., Landwehrmeyer G.B., Martinez-Mir M.I., Niznik H.B., Sunahara R.K., Seeman P., O'Dowd B.F., Probst A., and Palacios J.M. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem. Int. 20 Suppl. (1992) 33S-43S
17. Mennicken F., Savasta M., Peretti-Renucci R., and Feuerstein C. Autoradiographic localization of dopamine uptake sites in the rat brain with 3H-GBR 12935. J. Neural. Transm. Gen. Sect. 87 (1992) 1-14
18. Mesulam M.M. Frontal cortex and behavior. Ann. Neurol. 245 (1986) 320-325
19. Mountjoy K.G., and Wong J. Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mol. Cell Endocrinol. 36 (1997) 171-177
20. Nabeshima T., Kitaichi K., and Noda Y. Functional changes in neuronal systems induced by phencyclidine administration. Ann. N. Y. Acad. Sci. 801 (1996) 29-38
21. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., Ozaki N., Taguchi T., Tatsumi M., Kamijima K., Straub R.E., Weinberger D.R., Kunugi H., and Hashimoto R. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 279 (2004) 2699-2708
22. Pezze M.A., and Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog. Neurobiol. 93 (2004) 301-320
23. Pichler R., Sfetsos K., Badics B., Gutenbrunner S., and Aubock J. Vitiligo patients present lower plasma levels of alpha-melanotropin immunoreactivities. Neuropeptides 38 (2004) 177-183
24. Robinson D.G., Woerner M.G., Napolitano B., Patel R.C., Sevy S.M., Gunduz-Bruce H., Soto-Perello J.M., Mendelowitz A., Khadivi A., Miller R., McCormack J., Lorell B.S., Lesser M.L., Schooler N.R., and Kane J.M. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry 163 (2006) 2096-2102
25. Scatton B., Simon H., Le Moal M., and Bischoff S. Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci. Lett. 15 (1979) 125-131
26. Shayegan D.K., and Stahl S.M. Emotion processing, the amygdala, and outcome in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 94 (2005) 840-845
27. Sim K., DeWitt I., Ditman T., Zalesak M., Greenhouse I., Goff D., Weiss A.P., and Heckers S. Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI study. Schizophr. Bull. 32 (2006) 332-340
28. Steinpreis R.E., and Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res. 111 (1993) 263-270
29. Stevens J.R. An anatomy of schizophrenia?. Arch. Gen. Psychiatry 29 (1973) 177-189
30. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., Harris-Kerr C., Wormley B., Sadek H., Kadambi B., Cesare A.J., Gibberman A., Wang X., O'Neill F.A., Walsh D., and Kendler K.S. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71 (2002) 337-348
31. Swank R.T., Sweet H.O., Davisson M.T., Reddington M., and Novak E.K. Sandy: a new mouse model for platelet storage pool deficiency. Genet. Res. 58 (1991) 51-62
32. Torrey E.F., and Peterson M.R. Schizophrenia and the limbic system. Lancet 2 (1974) 942-946
33. Vickroy T.W., and Johnson K.M. Similar dopamine-releasing effects of phencyclidine and nonamphetamine stimulants in striatal slices. J. Pharmacol. Exp. Ther. 1 (1980) 669-674
34. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde T.M., Herman M.M., Weinberger D.R., and Kleinman J.E. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 9 (2004) 544-555
35. Zimmermann R.C., Krahn L.E., Klee G.G., Ditkoff E.C., Ory S.J., and Sauer M.V. Prolonged inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates the circadian rhythm of human TSH secretion. J. Soc. Gynecol. Invest. 8 (2001) 174-178